Relationship between urinary pH and efficacy of Bacillus Calmette-Guérin treatment in patients with carcinoma in situ of the bladder
Authors:
- 19 May 2025
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-6
Abstract
Purpose Bacillus Calmette-Guérin (BCG) is the standard treatment for carcinoma in situ (CIS) in patients with urothelial bladder carcinoma. We aimed to determine whether average urinary pH before BCG instillation affects the BCG response. Methods Between August 2003 and January 2023, 203 patients with CIS received BCG treatment (Tokyo strain, 80 mg, ≥ 5 times) at our hospital. Average urinary pH was calculated by summing each urinary pH measurement before BCG instillation and dividing by the number of instillations. The Fine-Gray method was used to assess the relationship between average urinary pH (as a continuous variable) and intravesical recurrence. We also analyzed the cumulative incidence of intravesical recurrence after BCG treatment using different cutoff values for average urinary pH (median and trisection of the cohort). Results The median follow-up period was 45 months (interquartile range (IQR): 14–83 months). The median urinary pH was 6.07 (IQR: 5.68‒6.50). In multivariate analysis, average urinary pH before BCG was significantly associated with intravesical recurrence (hazard ratio: 0.53, 95% confidence interval 0.32–0.89, p = 0.017). The cumulative incidence of intravesical recurrence differed significantly when categorized by average urinary pH (median and trisection), with patients having higher urinary pH showing lower intravesical recurrence rates. Conclusion This is the first study to examine the relationship between BCG response and average urinary pH in patients with CIS. Patients with higher urinary pH had lower intravesical recurrence rates after BCG treatment.Keywords
This publication has 20 references indexed in Scilit:
- An exploratory study investigating the impact of the bladder tumor microbiome on Bacillus Calmette Guerin (BCG) response in non-muscle invasive bladder cancerUrologic Oncology: Seminars and Original Investigations, 2024
- Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospectBiomedicine & Pharmacotherapy, 2020
- Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making toolUrologic Oncology: Seminars and Original Investigations, 2018
- Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancerCochrane Database of Systematic Reviews, 2017
- Sequential Combination of Mitomycin C Plus Bacillus Calmette-Guérin (BCG) Is More Effective but More Toxic Than BCG Alone in Patients with Non–Muscle-invasive Bladder Cancer in Intermediate- and High-risk Patients: Final Outcome of CUETO 93009, a Randomized Prospective TrialEuropean Urology, 2015
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-GuérinEuropean Urology, 2012
- Regulation of cancer cell metabolismNature Reviews Cancer, 2011
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- Bacterial ureases in infectious diseasesMicrobes and Infection, 2000